TRAIL: Treatment of Intracranial Aneurysms With LVIS® System (TRAIL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient or patient's legally authorized representative has been informed about the confidentiality of the study and has agreed to the collection of his/her personal data
Patient has a ruptured or unruptured intracranial aneurysm for which:
- The parent artery has a diameter ≥ 2.0mm and ≤ 4.5 mm;
- The aneurysm neck size is ≥ 4mm or its dome-to-neck ratio is < 2 (wide neck)
- Endovascular treatment with coils and one or more LVIS® devices has been determined necessary for the patient by the multidisciplinary team
- Patient is aged ≥ 18 years
- Patient presents with a WFNS score between 0 and 3
- Patient has agreed to attend follow-up appointments
Exclusion Criteria:
- The use of an endovascular stent other than LVIS® has been determined necessary
- Patient presents with medical or surgical co-morbidities limiting his/her life expectancy to less than one year
- Patient has a contraindication to platelet inhibition treatment
- Patient requires retreatment of an aneurysm previously treated with a stent
- Patient is pregnant
- Patient has multiple aneurysms to be treated in one procedure
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
LVIS®
|
Low-profile Visualized Intraluminal Support device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mortality rate
Time Frame: 6 months
|
6 months
|
|
Retreatment rate
Time Frame: 18 months
|
18 months
|
|
Anatomical stability of aneurysm treatment compared to the initial occlusion rate of the aneurysm
Time Frame: 6 months
|
6 months
|
|
Anatomical stability of aneurysm treatment compared to the initial occlusion rate of the aneurysm
Time Frame: 18 months
|
18 months
|
|
Retreatment rate
Time Frame: 6 months
|
6 months
|
|
Morbidity rate
Time Frame: 6 months
|
6 months
|
|
Morbidity rate
Time Frame: 18 months
|
18 months
|
|
Mortality rate
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Charbel Mounayer, Prof., CHU Limoges; Limoges, France
- Principal Investigator: Michel Piotin, M.D., Fondation Rothschild; Paris, France
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TRAIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.